Clinical features and IHC score for CD8 and GrzB staining of the 80 FL cases
| Variable . | Immunohistochemical analysis . | P . | |
|---|---|---|---|
| Group A . | Group B . | ||
| High GrzB . | Low GrzB . | ||
| % [95% CI], N = 48 . | % [95% CI], N = 32 . | ||
| Median age (range), y | 57.5 (26-83) | 58 (33-78) | .8742* |
| Sex | .121† | ||
| Male | 58 (n = 28) [43-72] | 41 (n = 13) (24-59] | |
| Female | 42 (n = 20) [28-57] | 59 (n = 19) [41-76] | |
| Stage | .628‡ | ||
| I | 4 (n = 2) [1-14] | 0 (0-11] | |
| II | 8 (n = 4) [1-20] | 9 (n = 3) [2-25] | |
| III | 17 (n = 8) [7-30] | 25 (n = 8) [11-43] | |
| IV | 71 (n = 34) [56-83] | 66 (n = 21) [47-81] | |
| FLIPI | .183† | ||
| Low risk (0-1) | 26 (n = 12) [14-40] | 9 (n = 3) [2-25] | |
| intermediate risk (2) | 32 (n = 15) [19-47] | 35 (n = 11) [19-53] | |
| High (≥ 3) | 42 (n = 20) [28-58] | 56 (n = 18) [38-74] | |
| GELF | .109* | ||
| GELF = 0 | 23 (n = 11) [12-38] | 9 (n = 3) [2-25] | |
| GELF > 0 | 77 (n = 36) [62-88] | 91 (n = 29) [75-98] | |
| BM involvement | 58 (n = 28) [43-72] | 63 (n = 20) [44-79] | .748* |
| Treatment | .592‡ | ||
| R-CHOP | 65 (n = 31) [49-78] | 50 (n = 16) [32-68] | |
| R-CVP | 17 (n = 8) [7-30] | 22 (n = 7) [9-40] | |
| R Fludarabine-mitoxantrone | 6 (n = 3) [13-17] | 9 (n = 3) [2-25] | |
| R-CHOP + R | 10 (n = 5) [3-23] | 19 (n = 6) [7-36] | |
| R Fludarabine-mitoxantrone + R | 2 (n = 1) [0-11] | 0 (0-11) | |
| Immunochemistry | |||
| % of CD8-positive cells | .001‡ | ||
| 1: < 10% | 0 (0-7) | 12 (n = 4) [4-29] | |
| 2: 10%-30% | 37 (n = 18) [24-53] | 66 (n = 21) [47-81] | |
| 3: 30%-40% | 44 (n = 21) [29-59] | 16 (n = 5) [5-33] | |
| 4: > 40% | 19 (n = 9) [9-33] | 6 (n = 2) [8-21] | |
| Score GrzB | |||
| % of GrzB-positive cells | NC | ||
| 1: < 10% | 8 (n = 4) [2-20] | 66 (n = 21) [47-81] | |
| 2: 10%-30% | 48 (n = 23) [33-63] | 34 (n = 11) [19-53] | |
| 3: > 30% | 44 (n = 21) [29-59] | 0 (0-11) | |
| Intensity of GrzB staining | NC | ||
| 1: + | 6 (n = 3) [1-17] | 75 (n = 24) [57-89] | |
| 2: ++ | 44 (n = 21) [29-59] | 25 (n = 8) [11-43] | |
| 3: +++ | 50 (n = 24) [35-65] | 0 (0-15) | |
| Variable . | Immunohistochemical analysis . | P . | |
|---|---|---|---|
| Group A . | Group B . | ||
| High GrzB . | Low GrzB . | ||
| % [95% CI], N = 48 . | % [95% CI], N = 32 . | ||
| Median age (range), y | 57.5 (26-83) | 58 (33-78) | .8742* |
| Sex | .121† | ||
| Male | 58 (n = 28) [43-72] | 41 (n = 13) (24-59] | |
| Female | 42 (n = 20) [28-57] | 59 (n = 19) [41-76] | |
| Stage | .628‡ | ||
| I | 4 (n = 2) [1-14] | 0 (0-11] | |
| II | 8 (n = 4) [1-20] | 9 (n = 3) [2-25] | |
| III | 17 (n = 8) [7-30] | 25 (n = 8) [11-43] | |
| IV | 71 (n = 34) [56-83] | 66 (n = 21) [47-81] | |
| FLIPI | .183† | ||
| Low risk (0-1) | 26 (n = 12) [14-40] | 9 (n = 3) [2-25] | |
| intermediate risk (2) | 32 (n = 15) [19-47] | 35 (n = 11) [19-53] | |
| High (≥ 3) | 42 (n = 20) [28-58] | 56 (n = 18) [38-74] | |
| GELF | .109* | ||
| GELF = 0 | 23 (n = 11) [12-38] | 9 (n = 3) [2-25] | |
| GELF > 0 | 77 (n = 36) [62-88] | 91 (n = 29) [75-98] | |
| BM involvement | 58 (n = 28) [43-72] | 63 (n = 20) [44-79] | .748* |
| Treatment | .592‡ | ||
| R-CHOP | 65 (n = 31) [49-78] | 50 (n = 16) [32-68] | |
| R-CVP | 17 (n = 8) [7-30] | 22 (n = 7) [9-40] | |
| R Fludarabine-mitoxantrone | 6 (n = 3) [13-17] | 9 (n = 3) [2-25] | |
| R-CHOP + R | 10 (n = 5) [3-23] | 19 (n = 6) [7-36] | |
| R Fludarabine-mitoxantrone + R | 2 (n = 1) [0-11] | 0 (0-11) | |
| Immunochemistry | |||
| % of CD8-positive cells | .001‡ | ||
| 1: < 10% | 0 (0-7) | 12 (n = 4) [4-29] | |
| 2: 10%-30% | 37 (n = 18) [24-53] | 66 (n = 21) [47-81] | |
| 3: 30%-40% | 44 (n = 21) [29-59] | 16 (n = 5) [5-33] | |
| 4: > 40% | 19 (n = 9) [9-33] | 6 (n = 2) [8-21] | |
| Score GrzB | |||
| % of GrzB-positive cells | NC | ||
| 1: < 10% | 8 (n = 4) [2-20] | 66 (n = 21) [47-81] | |
| 2: 10%-30% | 48 (n = 23) [33-63] | 34 (n = 11) [19-53] | |
| 3: > 30% | 44 (n = 21) [29-59] | 0 (0-11) | |
| Intensity of GrzB staining | NC | ||
| 1: + | 6 (n = 3) [1-17] | 75 (n = 24) [57-89] | |
| 2: ++ | 44 (n = 21) [29-59] | 25 (n = 8) [11-43] | |
| 3: +++ | 50 (n = 24) [35-65] | 0 (0-15) | |
On the basis of GrzB staining patients were classified in two groups: group A (high GrzB score) and group B (low GrzB score). Group A (high GrzB score) includes patients having score 4, 5, or 6. Group B (low GrzB score) includes patients having score 1, 2, or 3. Scores were calculated by adding values corresponding to: (i) the number of GrzB+ cells (ranging from 1 to 3: with 1 = < 10% GrzB+ cells; 2 = 10%-30% GrzB+ cells; 3 = > 30% GrzB+ cells out of the CD8+ cells) and (ii) values corresponding to the intensity of GrzB staining (ranging from 1 to 3: with 1 = +; 2 = ++; 3 = +++, as shown in supplemental Figure 1).
FL indicates follicular lymphoma; IHC, immunohistochemistry; CI, confidence interval; NC, not calculated; NR, not reached; FLIPI, Follicular Lymphoma International Prognostic Index; GELF, Groupe d'Etude des Lymphomes Folliculaires; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone; R-CHOP + R, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone and rituximab maintenance; R-Fludarabine-mitoxantrone + R, rituximab, fludarabine, mitoxantrone, rituximab maintenance; and GrzB, granzyme B.
Student test.
χ2 test.
Fischer exact test.